Europe preventive vaccines market was valued at $18.02 billion in 2022 and will grow by 5.1% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure.
Highlighted with 62 tables and 55 figures, this 142-page report "Europe Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire Europe preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
Based on Vaccine Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• mRNA Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pneumococcal Disease
• Poliovirus
• Hepatitis
• Influenza
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Human Papilloma Virus
• COVID-19
• Other Diseases
By Administration, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
By Patient, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Vaccine Type, Disease, and Administration over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 27
2.2 Major Growth Drivers 31
2.3 Market Restraints and Challenges 37
2.4 Emerging Opportunities and Market Trends 40
2.5 Porter's Fiver Forces Analysis 44
3 Segmentation of Europe Market by Vaccine Type 48
3.1 Market Overview by Vaccine Type 48
3.2 Live/Attenuated Vaccines 50
3.3 Inactivated Vaccines 51
3.4 Subunit Vaccines 52
3.5 Toxoid Vaccines 53
3.6 Conjugate Vaccines 54
3.7 mRNA Vaccines 55
3.8 Recombinant Vector Vaccines 56
3.9 Other Vaccines 57
4 Segmentation of Europe Market by Disease 58
4.1 Market Overview by Disease 58
4.2 Pneumococcal Disease 60
4.3 Poliovirus 61
4.4 Hepatitis 62
4.5 Influenza 63
4.6 Measles, Mumps, and Rubella (MMR) 64
4.7 Varicella 65
4.8 Human Papilloma Virus 66
4.9 COVID-19 67
4.10 Other Diseases 68
5 Segmentation of Europe Market by Administration 69
5.1 Market Overview by Administration 69
5.2 Intramuscular Route 71
5.3 Subcutaneous Route 72
5.4 Oral Route 73
5.5 Intravenous Injection 74
5.6 Other Administration Routes 75
6 Segmentation of Europe Market by Patient 76
6.1 Market Overview by Patient 76
6.2 Pediatric Vaccines 78
6.3 Adult Vaccines 80
7 European Market 2022-2032 by Country 82
7.1 Overview of European Market 82
7.2 Germany 85
7.3 U.K. 88
7.4 France 91
7.5 Spain 94
7.6 Italy 97
7.7 Russia 100
7.8 Rest of European Market 103
8 Competitive Landscape 105
8.1 Overview of Key Vendors 105
8.2 New Product Launch, Partnership, Investment, and M&A 108
8.3 Company Profiles 109
AstraZeneca plc 109
Bavarian Nordic A/S 111
China National Biotec Group Company Ltd. 114
CSL Ltd. 116
Daiichi Sankyo Co. Ltd 118
Emergent BioSolutions Inc. 120
GlaxoSmithKline plc 122
Johnson & Johnson 126
Merck & Co. 128
Moderna Inc. 130
Novavax, Inc. 131
Pfizer Inc. 133
Sanofi SA 137
Takeda Pharmaceutical Co. Ltd. 140
RELATED REPORTS 142
The Data Center Preventive Maintenance Services Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive la...
Industrial protective clothing constitutes specialized attire fabricated from engineered textiles intended to safeguard personnel operating amid potentially perilous occupational environments from exposure to myriad hazards inherent to industrial settings such as manufacturing plants, construction s...
The Vaccines Isothermal Boxes Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufactu...
Europe cutting tools market was valued at $6.85 billion in 2023 and will grow by 4.6% annually over 2023-2033. The growth is driven by the increasing production and manufacturing activities, improved operational efficiency and innovative design, and an increasing demand for power tools for DIY activ...
Europe paper machine clothing (PMC) market was valued at $ 631.1 million in 2023 and will grow by 3.6% annually over 2023-2033. The growth is driven by the increasing demand for paper and paper-based products across various industries, technological advancements in the papermaking process, the intro...
Europe endoscopy devices market was valued at $10.1 billion in 2023 and will grow by 5.9% annually over 2023-2033. The growth is driven by the increasing prevalence of chronic diseases, the growing demand for less invasive procedures, a rising adoption of disposable endoscopic components, growing ge...
Europe digital health and wellness market was valued at $100.9 billion in 2023 and will grow by 18.9% annually over 2023-2033. The growth is driven by an increasing number of chronic diseases, the growing investment in health and wellness programs, the increased use of smartphones and wearable devic...
Europe connected healthcare device market was valued at $16 billion in 2023 and will grow by 19.2% annually over 2023-2033. The growth is driven by the emergence of telehealth and telemedicine services, benefits such as reliability and effective patient monitoring, the penetration of mobile and inte...
Europe bioprocess technology market was valued at $6.56 billion in 2023 and will grow by 13.7% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing tech...
Europe biopharmaceuticals market was valued at $116.5 billion in 2023 and will grow by 8.6% annually over 2023-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical t...